CULLINAN THERAPEUTICS, INC. Comprehensive Income
CULLINAN THERAPEUTICS, INC. (CGEM) reported Comprehensive Income of -$218.73 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-03-10
- CULLINAN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$50.67M.
- CULLINAN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$50.24M.
- CULLINAN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-06-30 was -$69.95M.
- CULLINAN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-03-31 was -$47.86M.
- CULLINAN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$218.73M.
- CULLINAN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$167.39M.
- CULLINAN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$150.69M, a 237.68% decline from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was $109.45M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$50.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$100.91M derived: sum of 2 quarters · filed 2026-03-10 | -$170.86M derived: sum of 3 quarters · filed 2026-03-10 | -$218.73M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$50.24M 10-Q · filed 2025-11-06 | -$120.20M derived: sum of 2 quarters · filed 2025-11-06 | -$168.06M 10-Q · filed 2025-11-06 | -$216.81M derived: sum of 4 quarters · filed 2026-03-10 |
| 2025-06-30 | -$69.95M 10-Q · filed 2025-08-07 | -$117.82M 10-Q · filed 2025-08-07 | -$166.57M derived: sum of 3 quarters · filed 2026-03-10 | -$205.68M derived: sum of 4 quarters · filed 2026-03-10 |
| 2025-03-31 | -$47.86M 10-Q · filed 2025-05-08 | -$96.61M derived: sum of 2 quarters · filed 2026-03-10 | -$135.73M derived: sum of 3 quarters · filed 2026-03-10 | -$177.90M derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-12-31 | -$48.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$87.86M derived: sum of 2 quarters · filed 2026-03-10 | -$130.04M derived: sum of 3 quarters · filed 2026-03-10 | -$167.39M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$39.11M 10-Q · filed 2025-11-06 | -$81.29M derived: sum of 2 quarters · filed 2025-11-06 | -$118.64M 10-Q · filed 2025-11-06 | -$141.52M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$42.17M 10-Q · filed 2025-08-07 | -$79.52M 10-Q · filed 2025-08-07 | -$102.40M derived: sum of 3 quarters · filed 2025-08-07 | -$141.01M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$37.35M 10-Q · filed 2025-05-08 | -$60.23M derived: sum of 2 quarters · filed 2025-05-08 | -$98.84M derived: sum of 3 quarters · filed 2025-05-08 | -$131.44M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$22.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$61.49M derived: sum of 2 quarters · filed 2025-02-27 | -$94.09M derived: sum of 3 quarters · filed 2025-02-27 | -$150.69M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$38.61M 10-Q · filed 2024-11-07 | -$71.21M derived: sum of 2 quarters · filed 2024-11-07 | -$127.81M 10-Q · filed 2024-11-07 | -$153.26M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$32.60M 10-Q · filed 2024-08-08 | -$89.20M 10-Q · filed 2024-08-08 | -$114.65M derived: sum of 3 quarters · filed 2024-08-08 | -$139.75M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$56.60M 10-Q · filed 2024-05-15 | -$82.06M derived: sum of 2 quarters · filed 2024-05-15 | -$107.16M derived: sum of 3 quarters · filed 2024-05-15 | $67.24M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$25.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$50.55M derived: sum of 2 quarters · filed 2024-03-14 | $123.84M derived: sum of 3 quarters · filed 2024-03-14 | $109.45M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$25.10M 10-Q · filed 2023-11-08 | $149.30M derived: sum of 2 quarters · filed 2023-11-08 | $134.91M 10-Q · filed 2023-11-08 | $101.61M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $174.40M 10-Q · filed 2023-08-10 | $160.00M 10-Q · filed 2023-08-10 | $126.71M derived: sum of 3 quarters · filed 2023-08-10 | $109.42M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$14.39M 10-Q · filed 2023-05-11 | -$47.69M derived: sum of 2 quarters · filed 2023-05-11 | -$64.98M derived: sum of 3 quarters · filed 2023-05-11 | -$80.67M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$33.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$50.59M derived: sum of 2 quarters · filed 2023-03-09 | -$66.28M derived: sum of 3 quarters · filed 2023-03-09 | -$66.41M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$17.29M 10-Q · filed 2022-11-14 | -$32.98M derived: sum of 2 quarters · filed 2022-11-14 | -$33.11M 10-Q · filed 2022-11-14 | -$61.52M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$15.69M 10-Q · filed 2022-08-10 | -$15.82M 10-Q · filed 2022-08-10 | -$44.23M derived: sum of 3 quarters · filed 2022-08-10 | -$54.23M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$128.00K 10-Q · filed 2022-05-16 | -$28.54M derived: sum of 2 quarters · filed 2022-05-16 | -$38.54M derived: sum of 3 quarters · filed 2022-05-16 | -$46.98M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$28.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$38.41M derived: sum of 2 quarters · filed 2022-03-17 | -$46.85M derived: sum of 3 quarters · filed 2022-03-17 | -$51.80M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$10.00M 10-Q · filed 2021-11-09 | -$18.45M derived: sum of 2 quarters · filed 2021-11-09 | -$23.39M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$8.45M 10-Q · filed 2021-08-10 | -$13.39M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$4.94M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |